Dr. Reddy's Laboratories Ltd. (RDY)
Dr. Reddy's Q1 Earnings and Revenues Miss Estimates, Stock Down
RDY's fiscal Q1 earnings and revenues miss estimates as weaker North America generics sales hurt results, sending shares down 9%.
Dr. Reddy's Laboratories Limited (RDY) Q1 2027 Earnings Call Transcript
Dr. Reddy's Laboratories Limited (RDY) Q1 2027 Earnings Call Transcript
Dr. Reddy's Laboratories Q1 Earnings Call Highlights
Dr. Reddy's Laboratories NYSE: RDY reported a year-over-year revenue decline and sharply lower profitability for the first quarter of fiscal 2027, as lower lenalidomide sales and semaglutide API-related challenges weighed on results. Management said the company's base business, excluding lenalidomide, continued to grow at a double-digit rate across key geographies.
Dr. Reddy's Laboratories Flags Semaglutide Supply Delay, Says No Recall Risk
Dr. Reddy's Laboratories NYSE: RDY said a scale-up issue tied to the active pharmaceutical ingredient for its semaglutide injection will temporarily delay commercial supplies, though management emphasized that products already supplied to the market are not affected and do not raise patient safety concerns.
Dr. Reddy's Laboratories Limited (RDY) Discusses Manufacturing Issue and Process Review for Semaglutide Transcript
Dr. Reddy's Laboratories Limited (RDY) Discusses Manufacturing Issue and Process Review for Semaglutide Transcript
Dr. Reddy's Q4 Earnings and Revenues Miss Estimates, Stock Down
RDY stock down 5% on missing fiscal fourth-quarter 2026 earnings and revenue estimates as North America generics sales slumped.
Dr. Reddy's Laboratories Limited (RDY) Q4 2026 Earnings Call Transcript
Dr. Reddy's Laboratories Limited (RDY) Q4 2026 Earnings Call Transcript
3 Generic Drug Stocks to Watch Despite Industry Headwinds
Generic drugmakers face pricing pressure, but companies like TEVA, SDZNY and RDY are betting on complex generics and biosimilars to protect growth.
Dr. Reddy's Q3 Earnings Match Estimates, Revenues Rise Y/Y
RDY posts flat Q3 earnings, while revenues miss estimates as global generics growth lagged, pressured by weaker North America sales.
Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript
Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript
3 Generic Drug Stocks to Watch Amid Changing U.S. Landscape
Generic drugmakers face U.S. pricing pressure, but TEVA, SDZNY and RDY gain momentum through complex generics and biosimilars.
Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues
RDY posts a Q2 earnings and revenue beat as global generics drive growth, while new launches and biosimilar advances shape its pipeline.
